Financial Data and Key Metrics Changes - In Q4 2025, revenue was $33.4 million, down approximately 15% year-over-year, with same-store revenue declining 16% [14] - For the full year 2025, total revenue was $151.8 million, a decrease of approximately 15.8% compared to fiscal 2024 [15] - Adjusted EBITDA for Q4 was $2.5 million, representing a margin of 7.4%, an increase of $0.6 million and 2.8% margin expansion year-over-year [15] - Full year adjusted EBITDA was approximately $15 million, resulting in an adjusted EBITDA margin of approximately 10% [15] Business Line Data and Key Metrics Changes - The company reported improvements in lead and consult volumes, which have continued into 2026, contributing to improved revenue trends [5] - Over 100 skin removal surgeries were completed in Q4 2025, with expectations for ramp-up in 2026 as capabilities expand across all locations [8] Market Data and Key Metrics Changes - The skin tightening and skin removal market is projected to be as large as fat removal, representing a long-term sales opportunity exceeding $100 million [7] - The percentage of patients using financing for procedures was approximately 50% [14] Company Strategy and Development Direction - The company is focused on introducing new services to capture the GLP-1 market opportunity, enhancing sales and marketing strategies, and maintaining strong financial discipline [6] - Strategic exit from the only clinic outside North America was made to streamline operations [5] - The company aims to build on momentum and drive disciplined growth to create shareholder value [10] Management's Comments on Operating Environment and Future Outlook - Management noted that 2025 was a year of rebuilding and transformation, with same-store sales improving from down 22% at the start of 2025 to positive in February 2026 [5] - The company expects revenue in 2026 to range from $151 million to $157 million, reflecting approximately 3% comparable growth [17] - Management expressed confidence in the full-year outlook, citing improved trends and a focus on execution [22] Other Important Information - The company paid down $19 million of debt in 2025, with gross debt outstanding at $56 million at year-end [16] - A reconciliation matter related to intercompany transactions was identified, leading to immaterial changes in prior year balances, but had no impact on revenue or cash [13] Q&A Session Summary Question: Guidance for 1Q indicates a slight decline year-over-year, while full year 2026 revenue is expected to be up slightly. What is causing this change in seasonality? - Management acknowledged improved trends and emphasized the need for consistent results to meet guidance [22] Question: Can you provide insights on body sculpting trends outside of GLP-1 related procedures? - Management noted that the core business around body contouring and fat removal is holding steady, with GLP-1s expected to drive future demand [23] Question: What feedback have you received from customers and surgeons regarding excisional procedures? - Management reported positive early results from patients and comfort among surgeons, with plans to ramp up procedures throughout the year [27] Question: How should capital allocation be viewed going forward regarding debt pay down versus investments? - Management indicated that the priority remains on maintaining a healthy balance sheet while also investing back into the business for growth initiatives [29]

Core Insights - The company is transitioning from a device-placement model to a utilization-focused model to unlock the economic potential of its global installed base of over 36,000 units [1] - A 'medtech' approach is being adopted, shifting from relationship-driven sales to a value-based selling model that emphasizes clinical economic differentiation and ROI for providers [1] Performance Summary - Q4 performance was positively impacted by a favorable mix shift towards consumables, which grew by 1.7% year-over-year, leading to significant operating leverage and margin expansion [1] - Adjusted EBITDA for Q4 reached $15 million, indicating approximately 700 basis points of margin expansion despite a slight revenue decline [1] Market Trends - The aesthetics market is evolving into a lifestyle category that emphasizes prevention and routine care, benefiting HydraFacial's non-invasive and repeatable treatment profile [1] Strategic Initiatives - The 'utilization flywheel' is identified as the core strategy, where brand demand drives traffic, increasing device usage and high-margin consumables revenue [1] - The company is reactivating underleveraged assets like SkinStylus in the microneedling category to enhance its role as a comprehensive skin health platform [1]

Core Viewpoint - Evolus has achieved profitability, leading to a significant increase in its stock price by over 35% [1][4]. Group 1: Financial Performance - Evolus reported a revenue growth of 14% year over year, reaching $90.3 million in the fourth quarter [3]. - The company posted an operating profit of $4.2 million, a turnaround from a loss of $2.3 million in the same period last year [5][6]. - The gross margin for Evolus stands at 64.34% [5]. Group 2: Market Demand and Customer Satisfaction - The demand for Evolus' products, which improve the appearance of wrinkles and frown lines, is increasing, with reorder rates around 71% [3]. Group 3: Future Outlook - Evolus anticipates revenue growth of 10% to 13%, projecting revenues between $327 million and $337 million by 2026 [7]. - The company aims for sustainable profitability and meaningful free cash flow, which will provide financial flexibility for capital management and growth investments [7].

Financial Data and Key Metrics Changes - Global net revenue for Q4 2025 was $90.3 million, representing a 14% increase compared to Q4 2024, with Jeuveau revenue at $83.1 million and Evolysse at $7.2 million [13] - For the full year 2025, global net revenue reached $297.2 million, up 12% from 2024, marking the sixth consecutive year of double-digit growth [14] - Reported gross margin for Q4 was approximately 66%, with adjusted gross margin at about 67% [16] - GAAP operating expenses for Q4 were $55.1 million, down from $57.3 million in Q3, while non-GAAP operating expenses were $53 million, compared to $49.7 million in Q3 [17][18] Business Line Data and Key Metrics Changes - Jeuveau continues to capture over 14% of the U.S. market share, with sustained growth despite a declining procedural environment [8] - Evolysse, introduced in 2025, has seen over 3,000 customers purchase the product, expanding the company's presence and increasing overall share of injectable spend [9] - The Evolus Rewards program has grown to over 1.4 million treated patients, contributing to sustained share expansion [5] Market Data and Key Metrics Changes - International revenue nearly doubled year-over-year, now representing approximately 8% of global revenues, up from 5% in 2024 [14] - In key markets like the U.K., the company is approaching double-digit market share, reflecting strong positioning outside the U.S. [9] Company Strategy and Development Direction - The company aims to build a global performance beauty company centered on differentiated brands for cash pay consumers, with plans to introduce Estyme in Europe and expect FDA approval of Evolysse Sculpt [11][12] - The strategy includes a focus on education and training for clinicians, with over 14,000 clinicians trained in 2025 [6] Management's Comments on Operating Environment and Future Outlook - Management noted that 2025 was a unique year for the aesthetics market, with only the third decline in U.S. injectable procedural volumes in 25 years, yet the company achieved 12% revenue growth [10] - The outlook for 2026 includes expected revenue between $327 million and $337 million, representing 10% to 13% growth over 2025 results [22] Other Important Information - The company has entered into a revolving credit facility providing up to $30 million, which will be used for working capital needs [20] - The company does not plan to raise equity capital and remains sensitive to dilution [21] Q&A Session Summary Question: Has the growth of Evolus been primarily from early adopters? - Management indicated that the customer base is diversifying, with over 3,000 purchasing accounts contributing to Jeuveau revenue, and plans to broaden the customer base through sampling and training programs [28][29] Question: Can you provide details on the rebate program structure? - The rebate program is designed as a growth rebate for accounts purchasing over $50,000 or $100,000 in a quarter, aimed at encouraging clinics to commit more business to Evolus [42][43] Question: How is the overall marketing strategy structured for 2026? - The marketing strategy includes digital advertising, billboards, and co-promotions with beauty brands, all customized for clinics [46][48] Question: What are the assumptions regarding competitive launches in guidance? - Management expects new entrants in 2026 to create pressure but believes that established brands will maintain their market share through quality and customer satisfaction [60][61] Question: How is the seasonality trend for Q1? - The toxin market is showing solid demand, while the filler market remains pressured but not experiencing the same declines as in 2025 [86]

Core Insights - Galderma will present ten posters showcasing updates from its aesthetic portfolio at the IMCAS 2026 World Congress in Paris, focusing on regenerative biostimulation, HA, and neuromodulator treatments [1] - The company will emphasize its leadership in community education through various events, including two symposia and a live anatomy workshop [1]

Core Insights - Evolus Inc. is projected to double in value by 2026 despite recent challenges in consumer sentiment and inflationary pressures affecting demand for elective aesthetic procedures [1] - Mizuho has lowered Evolus's price target to $19 from $20 while maintaining an Outperform rating, reflecting a cautious outlook on the company's product estimates [1][3] Financial Performance - In Q3 2025, Evolus reported global net revenue of $69 million, a 13% year-over-year increase, driven by strong demand for its neurotoxin Jeuveau, which generated $63.2 million [2] - The new Hyaluronic Acid filler, Evolysse, contributed $5.7 million in revenue during the same quarter [2] - For the full year 2025, Evolus revised its total net revenue outlook to between $295 million and $305 million [2] Market Position and Challenges - Evolus holds a 14% market share in the US aesthetic neurotoxin market, supported by a customer loyalty program that has grown to over 1.3 million members, a 34% increase year-over-year [3] - The company added approximately 500 new purchasing accounts in Q3, indicating expansion in its professional customer base [3] - The US aesthetic market is facing challenges, particularly in consumer spending, with the HA filler market experiencing a double-digit decline, complicating Evolysse's market entry [3]

Core Insights - Bausch Health, Inc. (BHC) shares increased by 11% following the announcement of the acquisition of Wuhan Shibo Zhenmei Technology Co., Ltd. [1] - The acquisition allows Solta Medical, a subsidiary of Bausch Health, to take full control of its distribution in China, enhancing its market presence and operational efficiency [2][7] - The Chinese aesthetics market is rapidly growing, positioning Solta Medical to meet increasing demand for aesthetic treatments [3] Company Performance - Bausch Health reported better-than-expected third-quarter results for 2025, driven by its Salix and Solta businesses [4] - Solta Medical achieved revenues of $140 million, reflecting a 25% year-over-year increase, with a 24% organic growth primarily from the Asia Pacific region [8] - Despite recent gains, Bausch Health's shares have declined by 12.5% year-to-date, contrasting with the industry's growth of 23.7% [6] Financial Position - As of September 30, 2025, Bausch Health's long-term debt stood at $21 billion, with a cash balance of $1.3 billion [10]

Core Insights - The BeautyHealth Company has appointed Philippe Schaison, a global aesthetics leader, to its Board of Directors, effective October 30, 2025, which is expected to enhance the company's growth and innovation in the beauty and aesthetics sector [1][3]. Company Overview - The BeautyHealth Company (NASDAQ: SKIN) is a medtech and beauty company that provides millions of skin health experiences annually, focusing on personalizing skin health for diverse demographics [4]. Leadership Experience - Dr. Schaison has over 20 years of experience in the global aesthetics, biotech, and consumer health industries, having held leadership positions at notable companies such as Allergan Aesthetics and Johnson & Johnson [2][3]. - He currently serves as CEO of Soltégo, Inc. and holds various board positions in biomedical companies, showcasing his extensive industry expertise [2]. Strategic Impact - Brent Saunders, Executive Chairman of BeautyHealth, emphasized that Dr. Schaison's experience in scaling beauty businesses and driving innovation will be invaluable for the company, particularly in maximizing the potential of the Hydrafacial brand [3]. - Dr. Schaison will also contribute to the Compensation and Nominating & Corporate Governance Committees, expanding the board to eight directors [3].

Financial Data and Key Metrics Changes - Global net revenue for Q2 2025 was $69.4 million, a 4% increase compared to 2024, driven by the successful launch of Evolisse and international revenue growth [28] - Reported gross margin for Q2 was 65.3%, with adjusted gross margin at 66.5%, impacted by a higher mix of international sales and introductory pricing for Evolisse [28][29] - GAAP operating expenses for Q2 were $55.5 million, down from $61.8 million in Q1, while non-GAAP operating expenses were $54 million compared to $52.9 million in Q1 [30][31] - Non-GAAP operating loss in Q2 was $7.9 million, compared to non-GAAP operating income of $1.1 million in 2024 [31] Business Line Data and Key Metrics Changes - Jeuveau experienced its first year-over-year decrease since launch, reflecting a decline in consumer sentiment and procedural volumes in the U.S. aesthetic toxin market [6][8] - Evolisse generated $9.7 million in revenue in its first quarter, marking the strongest first-quarter filler launch in over a decade [18] - The company maintained a 14% market share in the toxin market through the first half of the year, an increase from 13% in 2024 [15] Market Data and Key Metrics Changes - Procedural volumes in the U.S. toxin category have decreased over the past three consecutive quarters, with a notable impact on Jeuveau demand in Q2 [8][10] - Surveys indicated a potential rebound in patient volume in the second half of the year, with a majority of practices expecting growth of over 10% [9] Company Strategy and Development Direction - The company revised its 2025 revenue guidance to a range of $295 million to $305 million, reflecting 11% to 15% growth over 2024 [11][34] - Evolisse is expected to contribute 10% to 12% of total revenue for 2025, with a focus on maintaining long-term growth and profitability [20][34] - The company aims to achieve $700 million in revenue by 2028, with a non-GAAP operating income margin of 20% [33][34] Management's Comments on Operating Environment and Future Outlook - Management noted that the market environment has been challenging, with a significant slowdown in demand observed in the last two weeks of Q2 [6][10] - Despite the challenges, management expressed confidence in the company's ability to deliver sustainable growth, supported by strong early adoption of Evolisse and ongoing international expansion [21][90] Other Important Information - The company has implemented strategic reductions in operating expenses, resulting in over $25 million in annualized savings, while maintaining investment in customer-facing activities [13][34] - Evolus Rewards program saw record redemptions of over $224,000, with 65% coming from repeat patients, indicating strong brand loyalty [16] Q&A Session Summary Question: What dynamics are being seen regarding reduced demand? - Management indicated that procedural demand declined in the high single digits, with the slowdown not driven by competitive dynamics but rather overall market conditions [36][38] Question: What was the impact of inventory buying on recorded revenue? - Management suggested that the initial revenue from Evolisse included both stocking and pull-through elements, making it difficult to quantify precisely [40] Question: How do you explain the improvement seen in July? - Management noted a significant shift in business in July, correlating with internal and third-party research indicating a potential rebound [41] Question: What are the expectations for toxin demand trends? - Management highlighted that overall procedural volume did slow in the first half of the year, with some competitors experiencing significant declines [51] Question: What promotional activities are planned for Q4? - Management mentioned adjustments to promotional strategies to help practices with pull-through, including collaborations with beauty magazines [54] Question: What is driving the current consumer sentiment? - Management noted that consumers earning $150,000 or less are feeling the pinch from increased prices and tariffs, impacting their spending on aesthetic treatments [67] Question: How does the company plan to achieve its 2028 targets? - Management reiterated confidence in reaching the $700 million target, emphasizing that the revised guidance does not change the long-term outlook [87]

Market Position and Growth - Evolus is gaining market share in the fast-growing neurotoxin market[16] - Jeuveau's share of the toxin market has increased from 4% in 2019 to 14% in 2025[19] - The global addressable market for neurotoxins and fillers is expected to grow to $7 billion in 2028[20] - Evolus International is expected to achieve $100 million in 2028[23] Financial Performance - The company has exhibited double-digit revenue growth for the fifth consecutive year[28] - Net revenue is projected to be between $295 million and $305 million in 2025, representing 11% to 15% growth over 2024[29, 118] - Evolysse contributed 10%-12% of total revenue for the full year 2025[108, 118] - The company is projecting $700 million total net revenue by 2028[119] Product and Strategy - The company's total addressable market expands by 78% with the addition of the injectable HA gel portfolio[16] - Evolysse was the strongest first quarter filler launch in over a decade[106] - Evolus Rewards program has over 1.2 million total enrollments in Q2 2025[62, 113] - 70% of toxin consumers also use a filler[74]